Knowledge Base Article

Some of you may remember the television series Columbo that featured an unkempt cigar-smoking detective in a long beige raincoat. Columbo seemed to ramble on aimlessly when questioning suspects and just as they thought he was finally leaving, he would turn back to them with “just one more thing…” This month CMS added or reminded providers of several “just one more thing” items in relation to existing National Coverage Determinations (NCDs).

TAVR Hospital Program Volume Requirements

Effective May 1, 2012, Medicare covers Transcatheter Aortic Valve Replacement (TAVR) procedures under coverage with evidence development (CED) for the treatment of symptomatic aortic stenosis when:

• Furnished according to a Food and Drug Administration (FDA) approved indication; and
• Certain conditions are met including requirements for individual hospitals in which TAVR procedures are performed.

Hospitals must meet the volume requirements specified in the TAVR national coverage determination (NCD 20.32) in order for the TAVR procedure to be eligible for Medicare coverage. These requirements apply to each hospital site individually and hospitals that do not meet these volume requirements are not eligible for waivers or exceptions.

1. To begin a TAVR program, the hospital (without TAVR experience) must have:
2. ≥ 50 total aortic valve replacements (AVRs) in the previous year prior to TAVR, including ≥ 10 high-risk patients; and
3. ≥ 2 physicians with cardiac surgery privileges; and
4. ≥ 1000 catheterizations per year, including ≥ 400 percutaneous coronary interventions (PCIs) per year.
5. To continue a TAVR program, the hospital (with TAVR experience) must maintain:
6. ≥ 20 AVRs per year or ≥ 40 AVRs every 2 years; and
7. ≥ 2 physicians with cardiac surgery privileges; and
8. ≥ 1000 catheterizations per year, including ≥ 400 percutaneous coronary interventions (PCIs) per year.

See MLN Matters Article SE1515 for complete information.

Hepatitis C Virus (HCV) Screening

Effective June 2, 2014, Medicare covers screening for HCV as described below:

1. Once in a lifetime for individuals not at high-risk born from 1945 to 1965.
2. Use HCPCS code G0472
3. Individuals born prior to 1945 and after 1965 that do not have risk factors are not eligible for this screening
4. Once in a lifetime for individuals at high-risk of HCV regardless of birth year. “High risk” is defined as persons with a current or past history of illicit injection drug use; and persons who have a history of receiving a blood transfusion prior to 1992.
5. Use HCPCS code G0472
6. ICD-9 diagnosis code V69.8 (ICD-10 code Z72.89) “other problems related to lifestyle” is required
7. Annually for high-risk individuals who have had continued illicit injection drug use since the prior negative screening test.
8. Use HCPCS code G0472
9. Diagnosis codes required - ICD-9 code V69.8 (ICD-10 code Z72.89) AND
10. ICD-9 diagnosis code 304.91 (unspecified drug dependence continuous) (ICD-10 code F19.20)

Rural Health Clinics (RHCs), Federally Qualified Health Centers (FQHCs) and Method II Critical Access Hospitals (CAHs) are not valid facilities for HCV screening services. See MLN Matters Article MM9200 for more information. CPT code 86803, HCV rapid antibody test, is not appropriate for reporting HCV screening – use HCPCS code G0472.

Coverage of MTWA Using Non-SA Methods

Medicare has covered Microvolt T-wave Alternans (MTWA) diagnostic testing for sudden cardiac death (SCD) from ventricular arrhythmias since March 2006 but only when analyzed by spectral analysis (SA) method.

• Effective for claims with dates of service on and after January 13, 2015, CMS removed the national non-coverage of the MMA method and now allows Medicare Administrative Contractors (MACs) to determine coverage at their discretion of MTWA diagnostic testing for the evaluation of patients at risk for SCD using analysis methods other than SA.
• Providers should report CPT 93025 (MTWA for assessment of ventricular arrhythmias) with the –KX modifier to attest that documentation is on file verifying the MTWA was performed using a method of analysis other than SA for the evaluation of patients at risk for SCD from ventricular arrhythmias and that all other NCD criteria were met. (Claims for MTWA using spectral analysis do not require the KX modifier).
• MLN Matters Article MM9162 contains a list of the diagnosis codes approved by CMS – this list may or may not be complete based on the discretion of the MACs.
• The MACs will not automatically adjust previously denied claims based on the new coverage guidelines but providers may bring these to the MAC’s attention within timely filing.